Bcl-2-family proteins are central regulators of cell life and death. At least three major classes of Bcl-2-family proteins have been delineated, including proapoptotic proteins that contain several conserved regions of sequence similarity (termed 'multidomain'). In mammals, the multidomain proteins (MDPs) of the Bcl-2 family include Bax, Bak, and Bok. The founding member of the MDP group of Bcl-2-family proteins was discovered by Stanley Korsmeyer and co-workers, initiating an exciting area of cell death research. The status of current knowledge about the mechanisms and functions of MDPs is reviewed here, and some areas for future research are outlined. Therapeutic opportunities emerging from a growing understanding of MDPs with respect to their threedimensional structures, biochemical actions, and roles in disease raise hopes that the foundation of basic research laid by Korsmeyer and others will eventually be translated into clinical benefits, leaving a legacy that benefits the world for many decades.
Introduction
In 1993, the first proapoptotic members of the Bcl-2-family were reported. Bax (Bcl-2 Antagonist X) was identified by the Korsmeyer group as a Bcl-2-interacting protein that opposed Bcl-2 and promoted apoptotic cell death. 1 Bcl-X S (Bcl-X short) was identified by the Thompson group as a proapoptotic isoform of Bcl-X, produced by alternative mRNA splicing. 2 Subsequent sequence alignment analysis led to the identification of conserved regions of amino-acid sequence similarity among the then growing family of both pro-and antiapoptotic Bcl-2 family proteins, resulting in the coining by Korsmeyer in 1994 of the term Bcl-2 Homology (BH) domain. 3 Over time, four BH domains would be delineated; BH1, BH2, BH3, and BH4.
Two general classes of proapoptotic Bcl-2/Bax family proteins exist: (1) Those that share several regions of sequence homology, specifically BH1, BH2, and BH3 domain (termed 'multidomain' proteins by Korsmeyer in approximately 2000 4 ) and (2) Those that share little sequence similarity, save for the conserved BH3 domain (termed 'BH3-only' proteins by Strasser and others 5 ). The mechanisms by which these two classes of pro-apoptotic Bcl-2/Bax-family proteins promote cell death are quite distinct. Multidomain proteins (MDPs) appear to possess intrinsic cell deathinducing activity, as evidenced for example by their ability to kill yeast when ectopically expressed in these simple eukaryotes. [6] [7] [8] Mammalian MDPs also kill plant cells when ectopically expressed. 9 In contrast, BH3-only proteins (BOPs) use their BH3 domains as ligands for engaging other members of the Bcl-2 family, either suppressing antiapoptotic proteins such as Bcl-2 and Bcl-X L , or activating MDPs such as Bax and Bak. 10 The MDPs of mammals include Bax, Bak, and Bok, while genes encoding BOPs number at least 18 in the human genome. 11 To date, the three-dimensional (3D) structure of only one MDP has been determined -namely, Bax, which consists of a bundle of a-helices resembling the pore-forming region of bacterial toxins such as Diphtheria Toxin and the Colicins. 12 Amazingly, the same protein fold is found in the antiapoptotic members of the Bcl-2 family, indicating that they evolved from a common ancestor but developed opposing phenotypes from a common fold. The hypothesis that the same protein fold can accommodate opposing cell death phenotypes may explain why the genomes of invertebrate organisms such as Caenorhabditis elegans seem to be perfectly competent to regulate programmed cell death using a single Bcl-2/Bax-like gene (e.g. Ced9). Nearly the same fold is also seen in the Bcl-2/Bax-family protein, Bid, which is usually considered a BOP rather than a MDP due to the lack of sequence similarity in BH1 and BH2. 13 
Physiological Roles of MDPs
Gene ablation studies in mice have provided insights into the physiological roles of MDPs in mammals. For example, investigations by Korsmeyer and co-workers [14] [15] [16] [17] [18] showed that homozygous disruption of bax in mice reveals roles for this MDP in neuronal cell death during development, homeostasis of lymphoid and reproductive organs, tumor suppression, and cell death responses to DNA damage, ischemia-reperfusion injury, and other forms of stress. Taking the nervous system as an example, Bax-deficient mice ('knockouts') have been shown to contain increased numbers of sympathetic and facial motor neurons, suggesting defective developmental neuronal cell death. 19 The absence of Bax in these mice also prevents 480% of the degeneration of facial motoneurons that normally occurs after axotomy. Moreover, embryonic neurons derived from Bax knockout mice are completely resistant to cell death induced by neurotrophic factor withdrawal, demonstrating an obligatory role for Bax in the death of sympathetic neurons when deprived of NGF. 19 Similarly, ablation of Bax expression using antisense oligonucleotides protects sympathetic neurons from apoptosis induced by NGF withdrawal. 20 Elevations in Bax expression occur in association with cell death induced by a variety of stimuli that may be of relevance to mechanisms of neuronal cell death during ischemia, epilepsy, spinal cord injury, and certain neurodegenerative diseases such as Parkinson's and Alzheimer's. For example, the human BAX gene promoter contains typical p53-binding sites and is transcriptionally upregulated by p53. 21 As elevations in p53 protein levels have been described as an early event during the neuronal cell deaths that occur in various models of forebrain ischemia and excitotoxic neurotransmitter administration, this functional connection between Bax and p53 indirectly suggests an potentially important role for Bax. [22] [23] [24] [25] Elevations in Bax protein levels have been documented as an early event associated with neuronal cell death during brain ischemia. Increases in Bax are found specifically in neurons that undergo cell death in ischemia-sensitive regions of the brain such as the CA1 sector of the hippocampus, in rat, hamster, and dog models of global cerebral ischemia. [26] [27] [28] Bax protein and mRNA levels also rapidly increase in neurons within the penumbra region of focal infarcts, in rodent models of middle cerebral artery occlusion. 29 Moreover, evidence suggesting a cause-and-effect relation between increases in Bax expression and ischemia-associated neuronal cell death has come from experiments using baxÀ/À mice generated by Korsmeyer et al. 30 Elevations in Bax protein and mRNA levels were described in neurons in vivo after excitotoxic lesion with the N-methyl-D-aspartate receptor agonist, quinolinic acid, 31 as well as after systemic administration of kainic acid. 32 Of potential relevance to neurodegenerative diseases, amyloidbeta peptide was reported to upregulate Bax and downregulate Bcl-2 in cultured human neurons, 33 and systemic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) has been shown to cause increases in Bax mRNA and protein in the substantia nigra. 34 In addition to neuronal cell death associated with ischemia and excitotoxic neurotransmitters, Bax protein levels are markedly increased in sensory and motor neurons following sciatic nerve transection, often in association with increases in Jun protein production. 35 In this regard, the bax gene promoter contains two consensus AP-1 sites, which theoretically could provide a functional connection between Jun and bax gene expression. Elevations in Jun expression have also been reported in association with neuronal cell death induced by neurotrophic factor withdrawal. Moreover, microinjection of neutralizing anti-Jun antibodies can prevent such cell deaths, 36 but it has not been determined whether Bax is involved under these circumstances. Increased Bax expression also has been observed in spinal motoneurons in patients with Amyotrophic Lateral Sclerosis (ALS). 37 Moreover, in transgenic mutant SOD1 mice (a model of ALS), Bax protein activation has been detected. 38 Marked elevations in Bax protein levels have been reported in microglial cells and astrocytes in association with apoptosis in patients with HIV-induced encephalitis. 39 Interestingly, elevations in Bax expression have also been reported in residual myocardiocytes surrounding infarcts in the heart, 40 suggesting that upregulation of Bax may be a common occurrence during ischemia and is not limited to the brain. Thus, Bax has emerged as a potential drug discovery target for ischemic and degenerative diseases.
Genetic analysis of the other MDPs, namely bak and bok, has been less insightful for delineating in vivo roles for these proapoptotic proteins in vivo. 41, 42 However, more should be done to investigate cell death regulation when these mice are stressed in various ways. Expression of the bok gene is limited to testis, ovary, and uterus in mice, 43 though expression of the human ortholog of this gene may be more widespread, including liver and kidney. 44 Genotoxic injury experiments using bokÀ/À mice did not reveal a requirement for bok for cell death in ovaries or other organs. 41 Expression of bak is widespread in mammalian tissues, 45 but no phenotypic abnormalities have been reported for bakÀ/À mice. 42 The combined knockout of bax and bak in mice results in developmental defects in several tissues due to failure to eradicate cells. Cells from bax/bak double-knockout mice are also resistant to myriad stimuli that are known to kill via the mitochondria-dependent pathway for cell death, including x-irradiation, UV-irradiation, DNA-damaging drugs, kinase inhibitor staurosporine, growth factor deprivation, and agents that induce ER stress, but not killing triggered by TNF-family death receptors. 42, 46 Perhaps because few baxÀ/ÀbakÀ/À mice survive to adulthood, these animals have not been employed widely for disease models aimed at assessing the importance of these MDPs for pathological cell death. However, in a model where intense UV-light is used to trigger photoreceptor cell death in the retina, combined deficiency of bax and bak was shown to provide protection. 47 Altogether, the observations from bax/bak double-knockout mice suggest that these MDPs individually play redundant roles in control of cell death, whereby simultaneous ablation of both genes provides a clear survival benefit. However, even bax/bak double knockout cells are susceptible to apoptosis induced by the extrinsic pathway (TNF-family death receptors) 42 and to autophagic cell death, 48 possibly explaining why several major organs in these mice are histological normal.
Cellular Actions of MDPs
The MDPs all contain a hydrophobic stretch of amino acids at the carboxyl-terminus that allows for their insertion into intracellular membranes. The favored locations of these proteins are the outer membrane of mitochondria and membranes of the endoplasmic reticulum (ER). The actions of MDPs at mitochondrial membranes have been extensively studied, providing evidence that these proteins control mitochondrial outer membrane permeability (MOP), thus promoting release of apoptogenic proteins such as cytochrome c from these organelles. 49, 50 How MDPs accomplish this feat is unclear, but their multimeric oligomerization in mitochondrial membranes (a phenomenon first demonstrated by Korsmeyer and co-workers) is correlated with MOP and release of intramitochondrial proteins. Several cell deathpromoting proteins are among those released from mitochondria in response to MDPs, thus triggering a variety of downstream caspase-dependent and caspase-independent cell death mechanisms, culminating in either apoptosis or necrosis.
The proapoptotic functions of MDPs at mitochondria are suppressed by antiapoptotic Bcl-2-family members that also target to the surface of these organelles. A variety of genetic and biochemical studies argue that MDPs are the effectors of the mitochondrial cell death pathway ( Figure 1 ), with antiapoptotic proteins such as Bcl-2 and Bcl-X L operating as upstream regulators that oppose the intrinsic death-inducing actions of MDPs such as Bax and Bak at mitochondrial membranes (see for example Wei et al. 46 and Cheng et al. 51 ). Although governing MOP perhaps through their intrinsic properties as pore-forming proteins, cross-talk between components of the inner mitochondrial membrane and MDPs in the outer membrane may also occur. For example, the adenine nucleotide translocator and F 0 F 1 -ATPase of the inner membrane can modulate the cell death activities of Bax, 52, 53 though it is also clear that Bax can induce cell death independently of these proteins. Bcl-2-family proteins also may modulate activity of the mitochondrial permeability transition pore, 54 a poorly understood regulator of inner membrane permeability. 55 The significance of whether MDPs exclusively affect MOP versus the possibility that they also control some aspects of inner membrane permeability resides at least in part in the need for inner membrane integrity to maintain the H þ gradient that creates the driving force for ATP generation and proper flow of electrons through the respiratory chain. Disruption of inner membrane function thus leads of generation of reactive oxygen species and ATP depletion, typically culminating in necrosis.
MDPs are also implicated in remodeling of the architecture of mitochondrial cristae, perhaps poising intermembrane proteins such as cytochrome c for rapid release. 56 Finally, MDPs have been implicated in pathological fission of mitochondria that often precedes cell death, where it has been reported that large aggregates of Bax and Bak accumulate at the sites of membrane constriction where pieces of these organelles are pinched off, through a process requiring Drp1. 57, 58 Still other actions of MDPs may exist at downstream points in the mitochondrial cell death pathway, based on a report that the Bok (Diva) binds caspase-activator Apaf1, 59 the cytochrome c-binding protein that links MOP to caspase activation.
The effects of MDPs on ER membranes are poorly understood, but a common observation is alteration in the handling of Ca 2 þ by this organelle. Loss of Bax and Bak causes essentially the same phenotype as over-expressing Bcl-2 or Bcl-X L with respect to ER Ca 2 þ -namely, it reduces internal ER Ca 2 þ stores, apparently by increasing the spontaneous rate of leakage of Ca 2 þ . 60, 61 The reduced Ca 2 þ accumulation in ER translates into a lower concentration of Ca 2 þ reached in the cytosol in response to stimuli that cause the ER to dump its sequestered Ca 2 þ , and a corresponding reduction in the downstream accumulation of Ca 2 þ into mitochondria. Accumulation of Ca 2 þ in mitochondria, when excessive, can lead to depolarization and loss of osmotic homeostasis, followed by organellar swelling and subsequent membrane rupture to release apoptogenic proteins, disturb electron transport, ablate ATP production, and cause cell death. 55 However, the reductions in resting ER Ca 2 þ seen in Bax/Bak doubly-deficient cells (or cells overexpressing Bcl-2 or Bcl-X L ) may have myriad other affects on Ca 2 þ -dependent signaling events in cells, and many of those may not be particularly germane to cell death regulation.
The hierarchy of Bcl-2/Bax-family protein actions at ER membranes is distinctly different from the situation at mitochondria. Bcl-2 and Bcl-X L remain capable of regulating ER Ca 2 þ even in Bax/Bak double-deficient cells that apparently express no MDPs 60 (and our unpublished data). As such, it seems that the antiapoptotic proteins (Bcl-2/Bcl-X L ) are the downstream effectors of ER Ca 2 þ levels, with Bax and Bak operating as upstream regulators that oppose the actions of proteins such as Bcl-2 and Bcl-X L (Figure 1 ). It is unknown whether the ability of Bcl-2 and Bcl-X L to control ER Ca 2 þ is a manifestation of their intrinsic function as ionchannels or an indirect consequence of their actions on Ca 2 þ channels in the ER. Indeed, evidence has been obtained to suggest an effect of Bcl-2 and/or Bcl-X L on Inositol Triphosphate (IP 3 )-gated Ca 2 þ channels (IP 3 Rs) or on the Ca 2 þ -ATPase of the ER, but many details are lacking that would unify all the available data into a coherent model. Figure 1 Hierarchy of functional interactions among Bcl-2-family proteins differs at mitochondria versus endoplasmic reticulum. The apparent hierarchies of functional interactions among Bcl-2-family proteins are contrasted for mitochondria (top) and ER (bottom). BOPs can be classified as type I proteins that function as antagonists of anti-apoptotic proteins such as Bcl-2 and Bcl-X L , and type II proteins that function both as antagonists of antiapoptotic Bcl-2-family proteins and as agonists of proapoptotic MDPs. Studies using genetically engineered cells lacking Bax and Bak by the Korsmeyer group played a major role in defining the hierarchical relations among the Bcl-2-family proteins activation of MDPs, implying that these proapoptotic proteins may reside in a latent state until provoked into action. For example, in most tissues, Bax is found in the cytosol rather than associated with membranous organelles, undergoing translocation to mitochondria in response to cell death stimuli. 69 The 3D solution structure of Bax in the soluble inactive state indicates that the C-terminal membraneanchoring domain is tucked into the same pocket that probably binds BH3 peptides. 12 In response to still poorly defined signals, Bax alters its conformation, forming dimers, exposing its C-terminal membrane-anchoring domain, and inserting into mitochondrial membranes. 70 The other MDPs in mammals, Bak and Bok, appear to reside constitutively within membranes. However, even though inserted in the outer mitochondrial membrane, oligomerization of Bax or Bak apparently must occur to trigger release of cytochrome c and other apoptogenic proteins. Studies first initiated by the Korsmeyer laboratory led to the demonstration that oligomerization of Bax and Bak in mitochondrial membranes occurs via a process that is promoted (perhaps even catalyzed) by agonistic BH3 domains provided by proteins such as Bid and Bim. [71] [72] [73] In 2002, Korsmeyer et al. 74 demonstrated that synthetic BH3 peptides that bind Bax or Bak recapitulate this activity, providing a means of triggering oligomerization experimentally. Synthetic unilammelar liposomes have been employed for attempting to identify the essential factors required for the Bax-mediated change in membrane permeability that account for release of proteins such as cytochrome c, revealing that the presence of cardiolipin in membranes and agonistic BH3 peptides (e.g. from Bid) are sufficient to trigger insertion of Bax into membranes, Bax oligomerization, and membrane permeabilization. 72 Altogether, the currently available data argue that MDPs exist in two conformational states, corresponding to monomeric inactive versus oligomeric active states -at least with respect to their role at mitochondrial membranes as inducers of MOP. (The functions of these proteins at ER membranes may be different.) Further, based on differences in alkaline extraction from membranes, the oligomeric form of Bax appears to represent a membrane integrated conformation, suggesting that oligomerization is associated with conversion of MDPs to their pore-forming conformation. A critical goal of future research should include defining the structure of this membrane-integrated, oligomeric state of MDPs and the molecular basis for their induction of MOP. In this regard, studies in which various molecular weight dextrans tagged with fluorochromes have been incorporated into synthetic liposomes imply that a discrete pore may not be created by Bax, 72 suggesting a more general disruption of membrane integrity where membranes rip apart, rather than a condition where a classical proteinaceous pore of discrete diameter is formed.
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Mechanisms of MDP Activation
Since the discovery by Korsmeyer et al. 75 of the first agonistic BH3-containing protein, Bid, several additional activators of MDPs have been identified. Among the nearly 20 BOPs, only Bid and Bim reportedly bind and activate MDPs. 73, 76 These agonistic BOPs are often found in latent, inactive states in cells, and must be summoned into action by appropriate stimuli or conditions. In the case of Bid, one elucidated activation mechanism involves cleavage by caspases or calpains, followed by myristoylation in some cases, and insertion into mitochondrial membranes (reviewed in Strasser 5 ). For Bim, the details depend on the isoform of the protein, as three forms of Bim have been described differing in length as a result of alternative mRNA splicing. The longest isoform of Bim, and usually the most abundant, is reportedly sequestered on microtubules in a complex with dynein light chain, and must be released to interact with membraneassociated Bcl-2-family proteins. 77 However, Bim proteins can also be found constitutively associated with mitochondria even under nonapoptotic conditions. 78 The phenotypes of mice in which the genes encoding Bid or Bim have been ablated are fairly normal (for details see Strasser 5 ), suggesting that additional agonists of MDPs are available to compensate for their loss. In this regard, antiapoptotic members of the Bcl-2-family may also serve as activators of MDPs under circumstances where the phenotype of these proteins is flipped, and the proteins undergo conformational changes that expose their hidden BH3 domains. For example, cleavage of Bcl-2 and Bcl-X L by caspases removes the first a-helix from these proteins and converts them into killers, probably functioning akin to BOPs. 79 Also, interaction of Bcl-2 with an orphan member of the nuclear receptor family, TR3/ Nur77, induces profound conformational changes in Bcl-2, consistent with exposure of its BH3 domain, and correlating with conversion from a protector to a killer. 80 Thus, these proapoptotic conformations of antiapoptotic Bcl-2-family proteins may also provide a means of triggering activation of MDPs, though definitive evidence is presently lacking that these proteins function as MDP agonists. Given that all antiapoptotic Bcl-2 family proteins possess a BH3 domain, it would be interesting to compare the BH3 peptides from the six antiapoptotic members of the mammalian Bcl-2-family for their ability to bind and activate the three mammalian MDPs, Bax, Bak, and Bok. Thus far, only Bcl-2 was tested, the BH3 domain of which failed to activate Bax/Bak. 81 Additional agonists of MDPs have been reported that contain no apparent BH3 domain, including the SH3-containing protein Bif-1, 82,83 the tumor suppressor p53, 84 and the caspase-activating adapter protein ASC. 85 Further studies are required to delineate physiological and pathological circumstances in which Bif-1, p53, and ASC play important roles in MDP activation in vivo.
Mechanisms of Suppression of MDPs
The classical suppressors of MDPs are antiapoptotic Bcl-2-family proteins. In 1993, Korsmeyer et al.
1 provided the first demonstration that proapoptotic and antiapoptotic members of the Bcl-2 family physically interact, mutually opposing each other. How physical interaction of Bcl-2 and various antiapoptotic members of the family inhibits the pro-apoptotic functions of MDPs such as Bax, Bak and Bok remains unclear. Various mutagenesis studies have suggested that anti-apoptotic proteins Bcl-2 and Bcl-X L can suppress cell death induction by Bax or Bak even without binding to these MDPs. 81, 86 In mammalian cells, this phenomenon can probably be attributed to antiapoptotic proteins sequestering the BH3 domains of MDP agonists such as Bid and Bim, thereby providing a reasonable explanation for the dissociation between binding and suppression of Bax/Bak-dependent killing. 87 However, non-binding mutants of Bcl-2 and Bcl-X L can also suppress killing of yeast by Bax, a cellular setting devoid of complications caused by Bid, Bim and other Bcl-2-family proteins. One possible explanation is that assays for detecting binding of Bcl-2 and Bcl-X L to MDPs typically have been biased towards conformations of these proteins associated with the nonmembrane integrated state. Thus, it may be that mutants of Bcl-2 and Bcl-X L that apparently have lost the ability to bind Bax or Bak in solution still remain competent to bind MDPs in their membrane-integrated conformations. Given that chemical crosslinking studies have provided evidence that Bcl-2 or Bcl-X L prevent the oligomerization of Bax or Bak in mitochondrial membranes, an attractive hypothesis is that Bcl-2, Bcl-X L , and the other antiapoptotic Bcl-2-family proteins function essentially as chain-terminating molecules ( Figure 2) . In this speculative model, MDPs such as Bax and Bak are envisioned as forming polymers in membranes that eventually connect at their ends, analogous to clasping the ends of beaded necklace, thereby creating membrane perturbations that lead to MOP. Antiapoptotic proteins such as Bcl-2 and Bcl-X L latch onto the ends of these polymers, preventing further chain extension. This model is consistent with biophysical studies of membrane permeabilization changes produced by purified Bax in synthetic liposomes in vitro, which have failed to provide evidence of a discrete pore and instead favor a more generalized disruption of membranes. 72 In addition to anti-apoptotic Bcl-2-family proteins, additional types of endogenous antagonists of MDPs have begun to emerge. For example, Ku70 is a noncatalytic subunit of the DNA-dependent protein kinase involved in responses to genotoxic injury. Ku70 was discovered to bind cytosolic Bax, preventing its translocation into mitochondrial membranes. 88 The region of Ku70 responsible was mapped to a minimal Bax-binding domain of five amino-acids, and a synthetic peptide corresponding to this region that was reported to suppress Bax translocation to mitochondria. 88, 89 It has been suggested that DNA-damage encourages Ku70 to associate with the DNA-dependent kinase and move into the nucleus, leaving Bax unattended in the cytosol. Moreover, acetylation of Ku70 may also promote its dissociation from Bax, providing a possible explanation for at least one of the many proapoptotic actions of chemical inhibitors of HDACs (reviewed in Yoo and Jones 90 ). Another antagonist of Bax is Humanin (HN), a small endogenous peptide of 26 amino-acids length in humans that binds to and inhibits Bax translocation to mitochondria. 91 HN was originally identified as an anti-apoptotic peptide encoded in a cDNA that rescued neuronal cells from apoptosis induced by presenilin mutants associated with familial Alzheimer's disease and by amyloid-beta-protein, during a functional screen of a cDNA library prepared from the brain of an autopsy-confirmed Alzheimer's disease patient. 92 Subsequently, Bax was identified among the possible cellular targets of this endogenous peptide. Mutagenesis studies of HN have so far revealed a perfect correlation between binding to Bax and ability of HN to suppress Bax-induced apoptosis. HN also suppresses Bax-mediated killing of yeast, implying that other proteins are not required. Further, direct highaffinity binding of HN to purified Bax has been demonstrated by fluorescence polarization assay. Based on the data available to date, it has been suggested that HN binds the Figure 2 Proposed model for chain-termination of Bax/Bak oligomers by anti-apoptotic Bcl-2-family proteins. Bax and Bak form large oligomers, a process blocked by anti-apoptotic Bcl-2-family proteins, Bcl-2 and Bcl-X L . A speculative model is proposed in which Bax or Bak form polymers in membranes, which can loop back to form closed structures that destabilize membranes. Bcl-2 and Bcl-X L play the role of chain terminators, preventing extension of the Bax/Bak polymers. Studies of Bax/Bak oligomerization by the Korsmeyer group have provided critical insights into the mechanisms by which these proteins induce MOP inactive conformation of Bax and helps to keep Bax inactivate in the cytosol. In addition, another mode of action of the HN peptide has recently been revealed, whereby HN binds the MDP agonists Bid and Bim-EL, preventing them from activating Bax and Bak. 93, 94 In this regard, though the 3D structure of Bim-EL is presently unknown, the structures of Bax and Bid are similar, implying that the HN peptide may recognize a conserved structural feature of these proteins. Understanding of the mechanism by which HN suppresses Bax, Bid, and BimEL would be greatly enhanced by the solving of the 3D-structure of a complex of HN with at least one of these proapoptotic proteins.
The Voltage-dependent anion channels (VDACs) are among the most abundant proteins of the outer mitochondrial membrane. Association of VDAC2 with Bak has been proposed by Korsmeyer et al. 95 as a mechanism for preventing oligomerization of Bak. Apoptotic stimuli induce dissociation of VDAC2 and Bak, through an unknown mechanism. 95, 96 Interestingly, VDAC1 has been reported to bind Bax, but the significance of this interaction is controversial. [97] [98] [99] [100] Altogether, the available data indicate that while MDPs may be interchangeable in terms of many or most of their effector functions, the upstream afferent inputs into these proteins vary considerably thus giving each MDP its unique biology (Figure 3 ).
Therapeutic Opportunities
Strategies for innovative therapies are beginning to emerge from the accumulating base of knowledge about MDPs and the cellular mechanisms that regulate their functions. Proof of concept experiments from the Korsmeyer group using agonistic BH3 peptides from Bid and Bim to activate MDPs imply that new therapies for inducing apoptosis of tumor cells could potentially be generated by identifying chemical compounds that mimic these BH3 peptides. 74 If proven to have an acceptable therapeutic index, such a strategy could complement the ongoing efforts to use compounds mimicking BH3 peptides to antagonize antiapoptotic Bcl-2-family proteins (reviewed in 101 ). However, somatic mutations that inactivate Bax or Bak in tumors, as well as reductions in the levels of their expression, may limit the ability of chemical agonists of MDPs to kill tumor cells. 102, 103 Relieving suppression of Bax by promoting dissociation of Ku70 represents another potential strategy for promoting apoptosis of cancer cells. HDAC inhibitory compounds reportedly induce hyperacetylation of Ku70, promoting release of Bax, 90 revealing at least one possible strategy. Cancer gene therapy interventions whereby Bax is delivered into tumors represents another approach to exploiting MDPs for cancer therapy. 104 For diseases where cytoprotection is the goal, such as stroke, myocardial infarction, and neurodegeneration, compounds that suppress MDPs are highly desired. A series of 3,6-dibromocarbazole piperazine derivatives of 2-propanol that suppress Bax have been described, providing a potential starting point for future attempts to optimize compound potency. 105 Using NMR-based strategies, compounds have also been synthesized that bind to and suppress the MDP agonist Bid, 106 evidently stabilizing the inactive conformation of this MDP-activating protein. Given that bid knockout mice are protected from cell loss in several disease models, including stroke and hepatitis, 107, 108 chemical inhibitors of MDP agonists could be useful for reducing tissue injury in certain disease scenarios. Another approach to MDP suppression is predicated on identification of compounds that mimick the 5 0 mer peptide from Ku70 that suppresses Bax activation. 89 Compounds that mimic the HN peptide could also be envisioned, and presumably would offer the advantage of simultaneously targeting three proapoptotic proteins, Bax, Bid, and BimEL. 91, 93, 94 While MDPs and their endogenous agonists are attractive targets for drug discovery with respect generating novel cytoprotective agents, the requirement for some of them for normal tissue homeostasis raises concerns about chronic suppression of these death-inducing proteins. For example, baxÀ/À mice have an increased risk of tumorigenesis, and bidÀ/À mice develop leukemia after a long latent phase. Thus, clinical use of chemical antagonists of MDPs and their endogenous agonists may be limited to acute injury situations. Nevertheless, given that myocardial infraction and stroke account directly or indirectly for over one-third of all deaths in the developed world, successful development of chemical inhibitors of these proapoptotic proteins could have a huge impact, even if relegated only to acute injury scenarios.
In vitro applications of compounds or even membranepermeable peptides that inhibit MDPs can also be envisioned for biomanufacturing processes where large-scale cell production is involved. Opportunities for ex vivo applications of chemical and peptidyl antagonists of MDPs are likely to expand as stem cell science makes strides towards cell replacement therapies for regenerative medicine.
Despite these many opportunities, it should be recognized that MDPs are challenging targets, as they lack enzymatic activity and thus do not fit the typical model of classical smallmolecule drug targets. Nevertheless, with modern advances in structure-based drug optimization, it may be possible to tailor compounds that bind sites on these proteins, either stabilizing their inactive conformations for suppressing death of wanted cells or triggering MDP oligomerization for inducing demise of unwanted cells. The accomplishments in discovery research made by Stanley Korsmeyer and others working in apoptosis research have created a platform for future therapies, leaving a legacy that will benefit the world for many years.
